Intensive community pharmacy intervention had little impact on triptan consumption: A randomized controlled trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Intensive community pharmacy intervention had little impact on triptan consumption : A randomized controlled trial. / Søndergaard, Jens; Foged, Annette; Kragstrup, Jakob; Gaist, David; Gram, Lars Freng; Sindrup, Søren Hein; Schaffalizky De Muckadell, Hans Ulrik; Larsen, Bente Overgaard; Herborg, Hanne; Andersen, Morten.
I: Scandinavian Journal of Primary Health Care, Bind 24, Nr. 1, 03.2006, s. 16-21.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Intensive community pharmacy intervention had little impact on triptan consumption
T2 - A randomized controlled trial
AU - Søndergaard, Jens
AU - Foged, Annette
AU - Kragstrup, Jakob
AU - Gaist, David
AU - Gram, Lars Freng
AU - Sindrup, Søren Hein
AU - Schaffalizky De Muckadell, Hans Ulrik
AU - Larsen, Bente Overgaard
AU - Herborg, Hanne
AU - Andersen, Morten
N1 - Funding Information: The authors would like to thank the pharmacies for their participation in the trial. The study was supported by The Danish Pharmacy Foundation (Apotekerfonden).
PY - 2006/3
Y1 - 2006/3
N2 - Objective. To evaluate the impact of an intensive pharmaceutical care campaign targeting inappropriate use of triptans. Design. Randomized controlled trial. Setting. 22 community pharmacies in the County of Funen, Denmark. Subjects. A total of 1123 triptan users at intervention pharmacies and 1340 at control pharmacies. Intervention. Intervention pharmacy staff received information on migraine and other types of headache, detection of inappropriate triptan use and other drug-related problems, and techniques for establishing a dialogue with patients. Intervention consisted of a folder and a structured dialogue with the pharmacy staff. The folder included questions aimed at detecting overuse and inappropriate triptan use. Main outcome measures. Change in average triptan consumption in doses per month measured by means of a prescription database with information on all purchases of reimbursed drugs at the level of the individual patient. Results. Overall, intervention had no statistically significant short-term impact on patients' consumption of triptans either among incident users (intervention/control ratio 1.02; 95% confidence interval 0.95 to 1.12), or among prevalent users (1.02; 0.97 to 1.08). No effects were observed after 6 and 9 months, apart from a possible borderline effect after 9 months among prevalent users with intermediate triptan consumption (0.93; 0.87 to 1.00). Conclusion. The pharmaceutical care campaign did not reduce the use of triptans.
AB - Objective. To evaluate the impact of an intensive pharmaceutical care campaign targeting inappropriate use of triptans. Design. Randomized controlled trial. Setting. 22 community pharmacies in the County of Funen, Denmark. Subjects. A total of 1123 triptan users at intervention pharmacies and 1340 at control pharmacies. Intervention. Intervention pharmacy staff received information on migraine and other types of headache, detection of inappropriate triptan use and other drug-related problems, and techniques for establishing a dialogue with patients. Intervention consisted of a folder and a structured dialogue with the pharmacy staff. The folder included questions aimed at detecting overuse and inappropriate triptan use. Main outcome measures. Change in average triptan consumption in doses per month measured by means of a prescription database with information on all purchases of reimbursed drugs at the level of the individual patient. Results. Overall, intervention had no statistically significant short-term impact on patients' consumption of triptans either among incident users (intervention/control ratio 1.02; 95% confidence interval 0.95 to 1.12), or among prevalent users (1.02; 0.97 to 1.08). No effects were observed after 6 and 9 months, apart from a possible borderline effect after 9 months among prevalent users with intermediate triptan consumption (0.93; 0.87 to 1.00). Conclusion. The pharmaceutical care campaign did not reduce the use of triptans.
KW - Community pharmacy service
KW - Drug therapy
KW - Drug utilization
KW - Humans
KW - Migraine
KW - Pharmaceutical services
KW - Pharmacists
KW - Physicians' practice patterns
KW - Prescribing
KW - Primary healthcare
KW - Randomized controlled trials
KW - Research
KW - Serotonin agonists
KW - Tension headache
UR - http://www.scopus.com/inward/record.url?scp=32344434736&partnerID=8YFLogxK
U2 - 10.1080/02813430500444916
DO - 10.1080/02813430500444916
M3 - Journal article
C2 - 16464810
AN - SCOPUS:32344434736
VL - 24
SP - 16
EP - 21
JO - Scandinavian Journal of Primary Health Care
JF - Scandinavian Journal of Primary Health Care
SN - 0281-3432
IS - 1
ER -
ID: 324149106